24/7 Wall St. has picked out some of the major companies in the health care sector that are moving ahead of the first presidential debate and added in some color for each.
Chris Lange 24/7 Wall St. has collected several big FDA decisions and mid- to late-stage trials that should be coming up in late-September and October.
24/7 Wall St. has collected several big FDA decisions and mid-to-late-stage trials that should be coming up in October. These catalyst events can make or break these companies.
As the markets continue to stumble through May, and the volatility appears to be creeping up some, the end of the first-quarter earnings parade has opened the door for insiders to buy…
A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an improved formulation to a patent expiry and the opening of the floodgates…
Exelixis shares were rising early Monday following the release of positive results from its late-stage trial of cabozantinib.
Chris Lange Exelixis Inc. (NASDAQ: EXEL) was up slightly in Tuesday’s trading session following positive results from a late stage trial. The company announced the presentation of positive data from subgroup analyses of METEOR,…
Chris Lange On the close Tuesday, the PowerShares Dynamic exchange traded funds (ETFs) are set for a rebalance. These four stocks that are expected to have huge buying on the close Tuesday.
24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of August and added some color.
It appears that Exelixis assumed now would be the best time to dilute following its most recent successful in clinical trial and get more bang for its buck.
Chris Lange The most recent clinical trial results may have put Exelixis back on the map as a potential buyout.
Chris Lange 24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how they have performed since before the ASCO news.
24/7 Wall St. has taken a look at a few of the major ASCO winners so far. Color and background information has also been added on each, as well as how shares…
Exelixis is seeing an outright implosion in its stock after news of its Phase 3 metastatic prostate cancer not meeting its primary endpoint.
Jon C. Ogg These are the top analyst upgrades and downgrades from 24/7 Wall St. for Tuesday, September 2, 2014.
